Precision medicine in early breast cancer—can this apply to radiotherapy?

Our understanding of breast cancer has improved by leaps and bounds over the past 5 decades. The Early Breast Cancer Trialists’ Collaborative Group has provided Level 1 evidence on the survival benefits of multi-modality management after surgery with polychemotherapy, radiotherapy and endocrine therapy in early breast cancer (1,2). While advancements in treatment has led to an improvement in disease-free and overall survival, we now increasingly realise that a one-size-fits-all strategy does not apply to all breast cancer patients.